Overview

Gender

female

Elizabeth Buck is co-founder and Executive VP, Discovery & Translational Sciences for Black Diamond Therapeutics. Dr. Buck was instrumental in developing Black Diamond’s MAPing platform though which she made critical discoveries leading our understanding of the properties of allosteric mutations in oncogene activation.

Dr. Buck has over 15 years of experience in oncology therapeutics in biotechnology and large pharma industries. Her expertise and productivity are evidenced by more than 40 peer reviewed publications and patents. Prior to joining Black Diamond, Dr. Buck was Assistant Director of Advanced Preclinical Pharmacology at OSI Pharmaceuticals, where she led discovery and translational research to advance a series of oncology programs to clinical development. During this role Dr. Buck managed multidisciplinary global teams and spearheaded major academic collaborations to progress programs to IND. Dr. Buck received her undergraduate degree in physics from the University of New Hampshire, Ph.D. in cellular and molecular biology from New York University / Mount Sinai School of Medicine, and completed postdoctoral work with Jim Wells at Sunesis Pharmaceuticals.